Amitriptyline spray as well as preparation method and application thereof
By preparing amitriptyline spray containing amitriptyline hydrochloride, disodium ethylenediaminetetraacetate and ethyl hydroxyphenyl ester, the existing amitriptyline treatment with low analgesic strength and great side effects of treating neuropathic pain. Problem, achieving rapid and lasting analgesic effects and promoting nerve repair without toxic side effects.
Patent Information
- Application Number
- CN202411287559.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-13
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2044-09-13
AI Technical Summary
The existing drugs for amitriptyline for treating neuropathic pain have low analgesia, poor treatment effect and many side effects, and lack stable and effective relief and treatment plans.
Provide an amitriptyline spray, using water as solvent, containing amitriptyline hydrochloride, disodium ethylenediaminetetraacetate, ethyl hydroxyphenyl ester and dimethyl sulfoxide, prepared by specific concentration combination and preparation method. , forming amitriptyline spray, used to relieve and treat neuropathic pain.
Amitriptyline spray can quickly and effectively relieve neuropathic pain. The analgesia time can last for 3 to 4 hours without obvious side effects. It has stability and high analgesic strength. It is suitable for long-term use to promote repair of damaged nerves.
Smart Images

Figure CN118903008A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of medical technology, and in particular to an amitriptyline spray and a preparation method and application thereof. Background Art
[0002] Neuropathic pain (NP) is a chronic pain caused by primary injury, dysfunction or various diseases of the somatic nervous system. The main causes include diabetic neuropathy, drug-induced neuropathy, traumatic nerve damage, herpes zoster, adverse reactions of cancer chemotherapy drugs, etc. It can be divided into central neuropathic pain and peripheral neuropathic pain according to the initial site of onset. The clinical manifestations are spontaneous burning, tingling, and tingling, accompanied by induced pain. It usually manifests as persistent and recurrent pain when lightly touched or cold. It is a common symptom of somatosensory nervous system diseases.
[0003] At present, the clinical treatment of NP is still difficult. The existing treatment methods cannot control the pain symptoms and improve the recurrence of NP in a short period of time. The existing therapeutic drugs also have defects such as low analgesic strength, poor treatment effect, and more side effects. Therefore, it brings great challenges to the clinical prevention and treatment of NP. Amitriptyline in tricyclic antidepressants (TCA) is suitable for the treatment of diabetic peripheral neuropathy, postherpetic neuralgia and neuropathic pain caused by central stroke. Its mechanism of action is to block the reuptake of serotonin and norepinephrine neurotransmitters. However, studies have found that oral administration of amitriptyline will produce central effects, leading to severe chest pain, rapid heartbeat, syncope, abnormal bleeding, impaired consciousness, delirium, auditory hallucinations, visual hallucinations and many other adverse drug events (ADEs), and even cause anticholinergic reactions, postural hypotension and toxic liver damage.
[0004] There is no amitriptyline preparation in the prior art that can stably and effectively relieve and / or treat neuropathic pain and has low toxicity and side effects. Summary of the invention
[0005] The purpose of the present invention is to provide an amitriptyline spray and a preparation method and application thereof, so as to solve the problems of low analgesic effect, poor therapeutic effect and more side effects in the prior art in the process of treating neuropathic pain.
[0006] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:
[0007] The invention provides an amitriptyline spray. The amitriptyline spray uses water as a solvent and comprises components with the following concentrations: 30-100 g / L of amitriptyline hydrochloride, 0.5-4 g / L of disodium edetate, 40-60 mL / L of dimethyl sulfoxide, and 5-15 mL / L of ethyl hydroxybenzoate solution.
[0008] Preferably, the amitriptyline spray uses water as a solvent and includes components in the following concentrations: 40-60 g / L amitriptyline hydrochloride, 1-3 g / L disodium edetate, 45-55 mL / L dimethyl sulfoxide, and 8-12 mL / L ethylparaben solution.
[0009] Preferably, the amitriptyline spray uses water as a solvent and includes components in the following concentrations: 50 g / L amitriptyline hydrochloride, 2 g / L disodium edetate, 50 mL / L dimethyl sulfoxide, and 10 mL / L ethylparaben solution.
[0010] Preferably, the ethyl hydroxybenzoate solution uses anhydrous ethanol as a solvent and comprises components with the following concentrations: 30-60 g / L of ethyl hydroxybenzoate and 300-600 mL / L of glycerol.
[0011] Preferably, the dosage form of the amitriptyline spray includes one of amitriptyline water spray, amitriptyline oil spray and amitriptyline gel spray.
[0012] The invention also provides a method for preparing the amitriptyline spray, comprising the following steps: mixing and dissolving amitriptyline hydrochloride, disodium ethylenediaminetetraacetate, dimethyl sulfoxide, ethyl hydroxybenzoate solution and water to obtain the amitriptyline spray.
[0013] The present invention also provides the use of the amitriptyline spray in preparing a medicine for relieving and / or treating neuropathic pain.
[0014] The present invention has the following technical effects and advantages:
[0015] The amitriptyline spray prepared by the present invention can relieve and treat neuropathic pain, has the advantages of stable properties, good skin absorption, fast analgesia, high analgesia, lasting analgesia, convenience in use, and no obvious stains left. Animal experiments have found that the amitriptyline spray of the present invention takes effect within 10 minutes after spraying, the analgesia time can last for 3 to 4 hours, and long-term administration helps to promote the repair of damaged nerves. All model mice were not found to have common side effects after administration of amitriptyline. BRIEF DESCRIPTION OF THE DRAWINGS
[0016] Figure 1 is the standard curve of amitriptyline hydrochloride;
[0017] Figure 2The liquid chromatograms of the reference substance and the test substance, where A is the liquid chromatogram of the reference substance and B is the liquid chromatogram of the test substance;
[0018] Figure 3 Figure 1 is a diagram of a neuropathic pain mouse model, where the left figure is a schematic diagram of a neuropathic pain mouse model, and the right figure is a real picture of a neuropathic pain mouse model;
[0019] Figure 4 Results of mechanical pain threshold measurement in mice;
[0020] Figure 5 Results of the cold pain response test in mice;
[0021] Figure 6 The results of the thermal pain response test in mice;
[0022] Figure 7 Schematic diagram of the measurement site of motor nerve conduction velocity in mice, in which S1 is the stimulating electrode at the sciatic notch of mice, S2 (R1) is the stimulating electrode at the ankle joint of mice or the double-needle recording electrode at the ankle joint of mice, R2 is the double-needle recording electrode at the first interosseous muscle of the mouse toe, and E is the reference electrode.
[0023] Figure 8 The results of motor nerve conduction velocity measurement in mice. DETAILED DESCRIPTION
[0024] The invention provides an amitriptyline spray, which uses water as a solvent and comprises components with the following concentrations: 30-100 g / L of amitriptyline hydrochloride, preferably 40-60 g / L, and more preferably 50 g / L; 0.5-4 g / L of disodium ethylenediaminetetraacetate, preferably 1-3 g / L, and more preferably 2 g / L; 40-60 mL / L of dimethyl sulfoxide, preferably 45-55 mL / L, and more preferably 50 mL / L; and 5-15 mL / L of ethylparaben solution, preferably 8-12 mL / L, and more preferably 10 mL / L.
[0025] In the present invention, the ethyl hydroxybenzoate solution uses anhydrous ethanol as a solvent and comprises components with the following concentrations: 30-60 g / L of ethyl hydroxybenzoate, preferably 50 g / L; and 300-600 mL / L of glycerol, preferably 500 mL / L.
[0026] In the present invention, the dosage form of the amitriptyline spray includes one of amitriptyline water spray, amitriptyline oil spray and amitriptyline gel spray.
[0027] The invention also provides a method for preparing the amitriptyline spray, comprising the following steps: mixing and dissolving amitriptyline hydrochloride, disodium ethylenediaminetetraacetate, dimethyl sulfoxide, ethyl hydroxybenzoate solution and water to obtain the amitriptyline spray.
[0028] In the present invention, the preparation method comprises the following steps: adding amitriptyline hydrochloride, disodium ethylenediaminetetraacetate, dimethyl sulfoxide and ethyl hydroxybenzoate solution into water in sequence, dissolving and mixing evenly to obtain amitriptyline spray.
[0029] The present invention also provides the use of the amitriptyline spray in preparing a medicine for relieving and / or treating neuropathic pain.
[0030] The technical solutions provided by the present invention are described in detail below in conjunction with the embodiments, but they should not be construed as limiting the protection scope of the present invention.
[0031] The test mice of the present invention are C57BL / 6J mice, with an age of 6 to 8 weeks and a body weight of 20 to 25 g, purchased from Liaoning Changsheng Biotechnology Co., Ltd.
[0032] In the experimental equipment of the present invention, the Ugo Basile cold / hot combination plate was purchased from Shanghai Yuchun Biotechnology Co., Ltd.
[0033] Example 1: Preparation of Amitriptyline Spray
[0034] (1) Dissolve 50 g of ethyl paraben in an appropriate amount of anhydrous ethanol, add 500 mL of glycerol and mix well, and then dilute to 1000 mL with anhydrous ethanol to obtain an ethyl paraben solution with a mass concentration of 5%;
[0035] (2) dissolving 50 g of amitriptyline hydrochloride in an appropriate amount of pure water to obtain an amitriptyline hydrochloride solution;
[0036] (3) Add 2 g of disodium ethylenediaminetetraacetate, 50 mL of dimethyl sulfoxide and 10 mL of 5% ethylparaben solution to the amitriptyline hydrochloride solution in sequence, and after they are completely dissolved and mixed evenly, dilute to 1000 mL with pure water and bottle to obtain an amitriptyline spray.
[0037] Example 2: Preparation of Amitriptyline Spray
[0038] (1) Dissolve 60 g of ethylparaben in an appropriate amount of anhydrous ethanol, add 600 mL of glycerol and mix well, then dilute to 1000 mL with anhydrous ethanol to obtain an ethylparaben solution with a mass concentration of 6%;
[0039] (2) dissolving 30 g of amitriptyline hydrochloride in an appropriate amount of pure water to obtain an amitriptyline hydrochloride solution;
[0040] (3) 0.5 g of disodium ethylenediaminetetraacetate, 60 mL of dimethyl sulfoxide and 5 mL of 6% ethylparaben solution were added to the amitriptyline hydrochloride solution in sequence, and after they were completely dissolved and mixed evenly, the volume was made up to 1000 mL with pure water and bottled to obtain an amitriptyline spray.
[0041] Example 3: Preparation of Amitriptyline Spray
[0042] (1) Dissolve 30 g of ethyl paraben in an appropriate amount of anhydrous ethanol, add 300 mL of glycerol and mix well, and then dilute to 1000 mL with anhydrous ethanol to obtain an ethyl paraben solution with a mass concentration of 3%;
[0043] (2) dissolving 70 g of amitriptyline hydrochloride in an appropriate amount of pure water to obtain an amitriptyline hydrochloride solution;
[0044] (3) 4 g of disodium ethylenediaminetetraacetate, 40 mL of dimethyl sulfoxide and 15 mL of 3% ethylparaben solution were added to the amitriptyline hydrochloride solution in sequence, and after they were completely dissolved and mixed evenly, the volume was made up to 1000 mL with pure water and bottled to obtain an amitriptyline spray.
[0045] Example 4: Preparation of Amitriptyline Spray
[0046] (1) Dissolve 50 g of ethyl paraben in an appropriate amount of anhydrous ethanol, add 500 mL of glycerol and mix well, and then dilute to 1000 mL with anhydrous ethanol to obtain an ethyl paraben solution with a mass concentration of 5%;
[0047] (2) dissolving 40 g of amitriptyline hydrochloride in an appropriate amount of pure water to obtain an amitriptyline hydrochloride solution;
[0048] (3) Add 1 g of disodium ethylenediaminetetraacetate, 55 mL of dimethyl sulfoxide and 8 mL of 5% ethylparaben solution to the amitriptyline hydrochloride solution in sequence, and after they are completely dissolved and mixed evenly, dilute to 1000 mL with pure water and bottle to obtain an amitriptyline spray.
[0049] Example 5: Preparation of Amitriptyline Spray
[0050] (1) Dissolve 50 g of ethyl paraben in an appropriate amount of anhydrous ethanol, add 500 mL of glycerol and mix well, and then dilute to 1000 mL with anhydrous ethanol to obtain an ethyl paraben solution with a mass concentration of 5%;
[0051] (2) dissolving 60 g of amitriptyline hydrochloride in an appropriate amount of pure water to obtain an amitriptyline hydrochloride solution;
[0052] (3) 3 g of disodium ethylenediaminetetraacetate, 45 mL of dimethyl sulfoxide and 12 mL of 5% ethylparaben solution were added to the amitriptyline hydrochloride solution in sequence, and after they were completely dissolved and mixed evenly, the volume was made up to 1000 mL with pure water and bottled to obtain an amitriptyline spray.
[0053] Comparative Example 1: Preparation of Amitriptyline Spray Adjuvant
[0054] (1) Dissolve 50 g of ethyl paraben in an appropriate amount of anhydrous ethanol, add 500 mL of glycerol and mix well, and then dilute to 1000 mL with anhydrous ethanol to obtain an ethyl paraben solution with a mass concentration of 5%;
[0055] (2) 2 g of disodium ethylenediaminetetraacetate, 50 mL of dimethyl sulfoxide and 10 mL of 5% ethylparaben solution were diluted to 1000 mL with pure water, mixed evenly and bottled to obtain an amitriptyline spray adjuvant.
[0056] Experimental Example 1: Determination of the active ingredient content of amitriptyline spray
[0057] (1) Solution configuration:
[0058] Preparation of methanol-water-triethylamine solution: Mix 60 mL of methanol, 0.3 mL of triethylamine and 40 mL of water, and adjust the pH to 3.1 with phosphoric acid to obtain a methanol-water-triethylamine solution;
[0059] Preparation of test sample: Take 1 mL of the amitriptyline spray prepared in Example 1, add methanol-water-triethylamine solution to make the volume to 50 mL, and obtain a test sample stock solution; then take 1 mL of the test sample stock solution, add methanol-water-triethylamine solution to make the volume to 50 mL, and obtain a test sample;
[0060] Preparation of reference substance: Mix 10 mg of amitriptyline hydrochloride standard with methanol and dissolve by ultrasonic for 10 minutes, then add methanol to make up to 25 mL to obtain reference substance stock solution; then take 1 mL of reference substance stock solution, add methanol-water-triethylamine solution to make up to 10 mL to obtain reference substance;
[0061] (2) Drawing a standard curve of amitriptyline hydrochloride: dilute the reference substance stock solution prepared in step (1) with methanol-water-triethylamine solution to a reference substance gradient solution with a concentration of 0.816 mg / mL, 1.631 mg / mL, 3.263 mg / mL, 6.525 mg / mL, 13.050 mg / mL and 26.100 mg / mL, respectively; perform liquid chromatography on the reference substance gradient solutions of each concentration, wherein the liquid chromatography conditions are as follows: octadecylsilane bonded silica gel is used as a filler, the methanol-water-triethylamine solution prepared in step (1) is used as a liquid chromatography mobile phase, the liquid chromatography wavelength is 240 nm, and the injection volume is 2 μL; calculate the peak area of the reference substance gradient solution of each concentration according to the external standard method, and draw a standard curve of amitriptyline hydrochloride, the results are as follows: Figure 1 As shown;
[0062] (3) Determination of the content of amitriptyline hydrochloride in amitriptyline spray: The test sample and the reference sample prepared in step (1) were subjected to liquid chromatography using the liquid chromatography conditions described in step (2), and the peak area and the content of amitriptyline hydrochloride were calculated using the external standard method. The results are as follows: Figure 2 shown.
[0063] The results showed that the regression equation of the standard curve of amitriptyline hydrochloride was y=3.0755x-0.3957(R 2 =0.9999), presenting a linear regression relationship, and the linear range is 0.816-26.100 mg / mL; according to the calculation results, it can be known that the content of amitriptyline hydrochloride in the amitriptyline spray of the present invention is 5.0157%.
[0064] Experimental Example 2: Mouse Modeling and Drug Administration
[0065] (1) Modeling: 28 adult male C57BL / 6J mice were divided into 4 groups, namely experimental group A, experimental group B, control group and blank group, with 7 mice in each group. The mice in experimental group A, experimental group B and control group were anesthetized by intraperitoneal injection of 50 mg / kg of sodium pentobarbital. The mice were then placed in a prone position, the surface hair near the right femur of the mice was cleaned, and an 8 mm longitudinal incision was made in the middle of the right femur to expose the subcutaneous muscle after iodine disinfection. The muscle was bluntly separated with hemostatic forceps to expose the sciatic nerve. Four chromic intestines were loosely ligated around the sciatic nerve with a 1 mm interval between the chromic intestines to obtain a neuropathic pain model (CCI model). Figure 3As shown; the mice in the blank group were not subjected to sciatic nerve ligation. The main characteristics of the CCI model are: moderate ligation of the sciatic nerve causes a certain degree of damage to the sciatic nerve, which in turn affects the distal nerve fibers, and the mechanical compression of the nerve by chromic intestine forms a chronic inflammatory response, thereby simulating the characteristics of neuropathic pain and inflammatory pain, accompanied by intraneural edema, focal ischemia and axonal degeneration. After the operation, the sciatic nerve was returned to its original position, the muscles were arranged, and the wound was sutured;
[0066] (2) Administration: The amitriptyline spray of Example 1 was sprayed near the right femur of the mice in the experimental group A and the experimental group B, 3 times a day, 4 sprays (1.5 mL) each time, for a total of 2 weeks, wherein the mice in the experimental group A were sprayed with amitriptyline spray again 0.5 h before the determination of behavioral and nerve conduction indices, and the mice in the experimental group B were not administered 0.5 h before the determination of behavioral and nerve conduction indices; the amitriptyline spray adjuvant of Comparative Example 1 was sprayed near the right femur of the mice in the control group, 3 times a day, 4 sprays (1.5 mL) each time, for a total of 2 weeks; the mice in the blank group were not administered.
[0067] Experimental Example 3: Determination of behavioral indicators of mice
[0068] (1) Determination of mechanical pain threshold of mice: Before modeling, 7 days after modeling and drug administration, and 14 days after modeling, each group of mice in Experimental Example 2 was placed in a plexiglass cage with a metal mesh bottom (10×10×10 cm). After acclimating to the environment for 15 min and being in a quiet state, the mechanical pain threshold of each group of mice was measured using a 37450 Ugo basile paw tactile tester. Specifically, the mechanical needle was controlled to vertically stimulate the skin of the middle part of the sole of each group of mice from bottom to top, and the stimulation intensity was set to gradually increase from 0 g to 10 g within 20 s. When each group of mice showed a rapid paw retraction reaction, the stimulation was stopped and the stimulation pressure value was recorded. The measurement was performed 3 times, with an interval of 5 min each time. The average of the 3 stimulation pressure values was taken as the mechanical pain threshold. The results are shown in Table 2. Figure 4 As shown;
[0069] (2) Determination of cold pain reaction in mice: After the administration of each group of mice in Experimental Example 2, the cold pain reaction was measured using an Ugo Basile cold / hot combination plate. Specifically, the temperature of the cold plate was lowered to 5±0.5°C, and the cold plate was isolated from the external environment with a fiberglass board to maintain a constant temperature. Each group of mice was placed on the cold plate. The mice licked their feet or lifted their feet because of the pain. The time when the mice licked or retracted their paws was observed and recorded. The results are as follows: Figure 5 As shown;
[0070] (3) Determination of thermal pain response in mice: After the administration of each group of mice in Experimental Example 2, the thermal pain response was measured using an Ugo Basile cold / hot combination plate. Specifically, the hot plate was heated to 55±0.5°C and isolated from the external environment with a fiberglass board to maintain a constant temperature. Each group of mice was placed on the hot plate. The mice licked their feet or lifted their feet because of the pain. The time when the mice licked or retracted their paws was observed and recorded. The results are as follows: Figure 6 As shown;
[0071] (4) Measurement of motor nerve conduction velocity (MNCV) in mice: After the administration of each group of mice in Experimental Example 2, each group of mice was subjected to pulse stimulation. Specifically, under the conditions of room temperature of 20±0.5°C and mouse body temperature of 37°C, the sciatic notch and ankle joint of each group of mice were stimulated using stimulation electrodes S1 / S2, and the ankle joint and first interosseous muscle of the toes were stimulated and recorded using double-needle recording electrodes R1 / R2. The reference electrode E was placed between electrode S1 and electrode S2 / R1 and between electrode S2 / R1 and electrode R2, and was 11 cm away from electrode S2 / R. Figure 7 As shown; each group of mice was given a single pulse square wave stimulation with a wave width of 0.1ms. The stimulation intensity was gradually increased first, and the biphasic compound action potential was recorded from the electrodes R1 / R2. Then the stimulation intensity was gradually reduced, and the recorded biphasic compound action potential gradually disappeared. The stimulation intensity was repeatedly adjusted, and the stimulation intensity when the compound action potential appeared or disappeared was used as the stimulation threshold and recorded; 1.5 times the stimulation threshold was used as the stimulation intensity, and the interval between each two stimulations was 5s. The potential value from the peak to the peak valley of the biphasic compound action potential was used as the amplitude value, and the time from the start of stimulation to the appearance of the action potential was recorded as the conduction time of the excitation signal. The measurement was repeated 10 times and the average value was calculated; the hind feet of each group of mice were straightened obliquely backward at an angle of 45° to the spine in a natural limb state, and the distance from the stimulation electrode to the recording electrode of each group of mice was measured along the position and direction of the sciatic nerve, and the MNCV was calculated. The results are shown in Figure 8 As shown;
[0072] The MNCV calculation formula is: MNCV = distance from the stimulation electrode to the recording electrode / conduction time.
[0073] The results show that spraying the amitriptyline spray of the present invention on the neuropathic pain model mice can improve the symptoms of the neuropathic pain of the mice, and the analgesic time can last for 3 to 4 hours without any toxic side effects. It shows that the administration of the amitriptyline spray of the present invention to the neuropathic pain model mice can quickly exert an analgesic effect, and long-term administration helps to promote the repair of damaged nerves. No possible skin damage caused by the amitriptyline spray was found during the administration process, and no related side effects of oral amitriptyline mentioned in the amitriptyline product instructions disclosed in the prior art were found.
[0074] It can be seen from the above embodiments that the present invention provides an amitriptyline spray and a preparation method and application thereof. The amitriptyline spray prepared by the present invention can relieve and treat neuropathic pain, and has the advantages of stable properties, good skin absorption, fast analgesic speed, high analgesic strength, lasting analgesic effect, and no toxic side effects.
[0075] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.
Claims
1. An amitriptyline spray, characterized in that, The amitriptyline spray uses water as a solvent and comprises components with the following concentrations: 30-100 g / L amitriptyline hydrochloride, 0.5-4 g / L disodium edetate, 40-60 mL / L dimethyl sulfoxide, and 5-15 mL / L ethylparaben solution.
2. The amitriptyline spray according to claim 1, characterized in that The amitriptyline spray uses water as a solvent and comprises components in the following concentrations: 40-60 g / L amitriptyline hydrochloride, 1-3 g / L disodium edetate, 45-55 mL / L dimethyl sulfoxide, and 8-12 mL / L ethylparaben solution.
3. The amitriptyline spray according to claim 1 or 2, characterized in that The amitriptyline spray uses water as a solvent and includes components in the following concentrations: 50 g / L amitriptyline hydrochloride, 2 g / L disodium edetate, 50 mL / L dimethyl sulfoxide, and 10 mL / L ethylparaben solution.
4. The amitriptyline spray according to any one of claims 1 to 3, characterized in that The ethyl hydroxybenzoate solution uses anhydrous ethanol as a solvent and comprises components with the following concentrations: 30-60 g / L of ethyl hydroxybenzoate and 300-600 mL / L of glycerol.
5. The amitriptyline spray according to any one of claims 1 to 3, characterized in that The dosage form of the amitriptyline spray includes one of an amitriptyline water spray, an amitriptyline oil spray and an amitriptyline gel spray.
6. The method for preparing the amitriptyline spray according to any one of claims 1 to 5, characterized in that: The method comprises the following steps: mixing and dissolving amitriptyline hydrochloride, disodium ethylenediaminetetraacetate, dimethyl sulfoxide, ethyl hydroxybenzoate solution and water to obtain amitriptyline spray.
7. Use of the amitriptyline spray according to any one of claims 1 to 5 in the preparation of a medicament for relieving and / or treating neuropathic pain.
Citation Information
Patent Citations
Substituted indole ketone derivative as tyrosine kinase inhibitor
CN103848814A
Method and composition for treating and preventing irritation of the eyes
US4370324A
Method and composition for treating and preventing irritation of the eyes
US4505909A
Method to treat smoking withdrawal symptoms by potentiated central noradrenergic blocking
US4788189A
